Malaria: an update on current chemotherapy

Bibliography

• Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359:2619-20
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67
   PubMed Web of Science ®Google Scholar
• Hamed K, Grueninger H. Coartem(R): a decade of patient-centric malaria management. Expert Rev Anti Infect Ther 2012;10:645-59
   PubMed Web of Science ®Google Scholar
• Svennas KL, Macdonald SJ, Willis PA. Small molecule anti-malarial patents: a review (January 2010-June 2011). Expert Opin Ther Pat 2012;22:607-43
   PubMed Web of Science ®Google Scholar
• Tschan S, Kremsner PG, Mordmuller B. Emerging drugs for malaria. Expert Opin Emerg Drugs 2012;17:319-33
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev 2008;21:466-72
   PubMed Web of Science ®Google Scholar
• van Vugt M, van Beest A, Sicuri E, et al. Malaria treatment and prophylaxis in endemic and nonendemic countries: evidence on strategies and their cost-effectiveness. Future Microbiol 2011;6:1485-500
   PubMedGoogle Scholar
• Schumacher RF, Spinelli E. Malaria in children. Mediterr J Hematol Infect Dis 2012;4:e2012073
   PubMedGoogle Scholar
• Meremikwu MM, Donegan S, Sinclair D, et al. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012;2:CD003756
   Google Scholar
• Roggelin L, Cramer JP. Malaria prevention in the pregnant traveller: a review. Travel Med Infect Dis 2014;12:229-36
   PubMed Web of Science ®Google Scholar
• Dramowski A, Frigati L, Rabie H, et al. Malaria in children - prevention and management. Infect Disord Drug Targets 2013;13:303-11
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34
   PubMed Web of Science ®Google Scholar
• Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009;CD007483
   PubMed Web of Science ®Google Scholar
• Makanga M, Bassat Q, Falade CO, et al. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 2011;85:793-804
   PubMed Web of Science ®Google Scholar
• Naing C, Racloz V, Whittaker MA, et al. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. PLoS One 2013;8:e78819
   PubMed Web of Science ®Google Scholar
• Obonyo CO, Juma EA. Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J 2012;11:2
   PubMedGoogle Scholar
• van Eijk AM, Terlouw DJ. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev 2011;CD006688
   PubMedGoogle Scholar
• Whegang Youdom S, Samson A, Basco LK, et al. Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations. Malar J 2012;11:147
   PubMedGoogle Scholar
• Zwang J, Dorsey G, Djimde A, et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J 2012;11:260
   PubMedGoogle Scholar
• Organization WH. Guidelines for the treatment of malaria. 2nd edition. 2010. Available from: www.who.int/malaria/publications/atoz/9789241547925/en/index.html
   Google Scholar
• Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009;7:999-1013
   PubMed Web of Science ®Google Scholar
• Fehintola FA, Adedeji AA, Gbotosho GO, et al. Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children. J Infect Chemother 2008;14:188-94
   PubMedGoogle Scholar
• Douglas NM, Simpson JA, Phyo AP, et al. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis 2013;208:801-12
   PubMed Web of Science ®Google Scholar
• Medhi B, Patyar S, Rao RS, et al. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology 2009;84:323-32
   PubMed Web of Science ®Google Scholar
• Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 2004;147:99-107
   PubMed Web of Science ®Google Scholar
• Ogutu B. Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Expert Opin Pharmacother 2013;14:643-54
   PubMed Web of Science ®Google Scholar
• Abuaku B, Duah N, Quaye L, et al. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J 2012;11:388
   PubMedGoogle Scholar
• Jiao X, Liu GY, Shan CO, et al. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health 1997;28:476-81
   PubMedGoogle Scholar
• Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001;64:247-56
   PubMed Web of Science ®Google Scholar
• van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 2000;94:545-8
   PubMed Web of Science ®Google Scholar
• Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005;365:1467-73
   PubMed Web of Science ®Google Scholar
• van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999;61:964-7
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Adam I. Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther 2013;11:125-35
   PubMed Web of Science ®Google Scholar
• Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006;42:1570-7
   PubMed Web of Science ®Google Scholar
• Mayxay M, Khanthavong M, Lindegardh N, et al. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic. Clin Infect Dis 2004;39:1139-47
   PubMedGoogle Scholar
• Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007;297:2210-19
   PubMed Web of Science ®Google Scholar
• Abdulla S, Sagara I, Borrmann S, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008;372:1819-27
   PubMed Web of Science ®Google Scholar
• Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009;339:b2763
   PubMedGoogle Scholar
• Adjei GO, Kurtzhals JA, Rodrigues OP, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008;7:127
   PubMed Web of Science ®Google Scholar
• Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009;49:1629-37
   PubMed Web of Science ®Google Scholar
• Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009;4:e7871
   PubMed Web of Science ®Google Scholar
• Bell DJ, Wootton D, Mukaka M, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J 2009;8:204
   PubMedGoogle Scholar
• Carrasquilla G, Baron C, Monsell EM, et al. Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2012;86:75-83
   PubMed Web of Science ®Google Scholar
• Eshetu T, Abdo N, Bedru KH, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia. Malar J 2012;11:240
   PubMedGoogle Scholar
• Espie E, Lima A, Atua B, et al. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malar J 2012;11:174
   PubMedGoogle Scholar
• Falade CO, Ogunkunle OO, Dada-Adegbola HO, et al. Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children. Malar J 2008;7:246
   PubMed Web of Science ®Google Scholar
• Juma EA, Obonyo CO, Akhwale WS, et al. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in Western Kenya. Malar J 2008;7:262
   PubMedGoogle Scholar
• Thimasarn K, Sirichaisinthop J, Chanyakhun P, et al. A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand. Southeast Asian J Trop Med Public Health 1997;28:465-71
   PubMedGoogle Scholar
• Looareesuwan S, Wilairatana P, Viravan C, et al. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1997;56:613-17
   PubMed Web of Science ®Google Scholar
• Looareesuwan S, Kyle DE, Viravan C, et al. Treatment of patients with recrudescent falciparum malaria with a sequential combination of artesunate and mefloquine. Am J Trop Med Hyg 1992;47:794-9
   PubMed Web of Science ®Google Scholar
• Luxemburger C, ter Kuile FO, Nosten F, et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1994;88:213-17
   PubMed Web of Science ®Google Scholar
• Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994;170:971-7
   PubMed Web of Science ®Google Scholar
• Krudsood S, Looareesuwan S, Silachamroon U, et al. Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand. Am J Trop Med Hyg 2002;67:465-72
   PubMedGoogle Scholar
• van Vugt M, Leonardi E, Phaipun L, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 2002;35:1498-504
   PubMedGoogle Scholar
• Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 2013;57:818-26
   PubMed Web of Science ®Google Scholar
• Nambozi M, Van Geertruyden JP, Hachizovu S, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011;10:50
   PubMedGoogle Scholar
• Valecha N, Phyo AP, Mayxay M, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 2010;5:e11880
   PubMed Web of Science ®Google Scholar
• Trung TN, Tan B, Van Phuc D, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med 2009;15:189-92
   PubMedGoogle Scholar
• Bonnet M, Broek I, van Herp M, et al. Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar J 2009;8:192
   PubMedGoogle Scholar
• Nahum A, Erhart A, Gazard D, et al. Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa. Malar J 2007;6:170
   PubMedGoogle Scholar
• Guthmann JP, Ampuero J, Fortes F, et al. Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg 2005;99:485-92
   PubMed Web of Science ®Google Scholar
• Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010;375:1457-67
   PubMed Web of Science ®Google Scholar
• Kayentao K, Doumbo OK, Penali LK, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J 2012;11:364
   PubMedGoogle Scholar
• Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012;366:1298-309
   PubMed Web of Science ®Google Scholar
• Poravuth Y, Socheat D, Rueangweerayut R, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011;6:e14501
   PubMed Web of Science ®Google Scholar
• Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50-5
   PubMed Web of Science ®Google Scholar
• Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998;26:946-53
   PubMed Web of Science ®Google Scholar
• Ringwald P, Bickii J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 1996;347:24-8
   PubMed Web of Science ®Google Scholar
• Bukirwa H, Unnikrishnan B, Kramer CV, et al. Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014;3:CD006404
   Google Scholar
• Tinto H, Diallo S, Zongo I, et al. Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Trop Med Int Health 2014;19(4):469-75
   PubMedGoogle Scholar
• Borrmann S, Adegnika AA, Matsiegui PB, et al. Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis 2004;189:901-8
   PubMed Web of Science ®Google Scholar
• Borrmann S, Issifou S, Esser G, et al. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis 2004;190:1534-40
   PubMed Web of Science ®Google Scholar
• Oyakhirome S, Issifou S, Pongratz P, et al. Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother 2007;51:1869-71
   PubMed Web of Science ®Google Scholar
• Ruangweerayut R, Looareesuwan S, Hutchinson D, et al. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria. Malar J 2008;7:225
   PubMed Web of Science ®Google Scholar
• Lanaspa M, Moraleda C, Machevo S, et al. Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2012;56:2923-8
   PubMed Web of Science ®Google Scholar
• Tjitra E, Hasugian AR, Siswantoro H, et al. Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J 2012;11:153
   PubMedGoogle Scholar
• Meremikwu MM, Odey F, Oringanje C, et al. Open-label trial of three dosage regimens of fixed-dose combination of artemisinin and naphthoquine for treating uncomplicated falciparum malaria in Calabar, Nigeria. Malar J 2012;11:413
   PubMedGoogle Scholar
• Liu R, Dong HF, Jiang MS. A pharmacokinetic approach to assess artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria. Expert Rev Clin Pharmacol 2012;5:521-4
   PubMed Web of Science ®Google Scholar
• Batty KT, Salman S, Moore BR, et al. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob Agents Chemother 2012;56:2472-84
   PubMed Web of Science ®Google Scholar
• Benjamin J, Moore B, Lee ST, et al. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob Agents Chemother 2012;56:2465-71
   PubMed Web of Science ®Google Scholar
• Kinde-Gazard D, Ogouyemi-Hounto A, Capo-Chichi L, et al. [A randomized clinical trial comparing the effectiveness and tolerability of artemisinine-naphthoquine (Arco(R)) and artemether-lumefantrine (Coartem(R)) in the treatment of uncomplicated malaria in Benin]. Bull Soc Pathol Exot 2012;105:208-14
   PubMedGoogle Scholar
• Toure OA, Penali LK, Yapi JD, et al. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d’Ivoire. Malar J 2009;8:148
   PubMedGoogle Scholar
• Tun T, Tint HS, Lin K, et al. Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Acta Trop 2009;111:275-8
   PubMedGoogle Scholar
• Wang JY, Shan CQ, Fu DD, et al. [Efficacy of naphthoquine, artemisinine and a combination of the two drugs in the treatment of falciparum malaria]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003;21:131-3
   PubMedGoogle Scholar
• Guo WZ, Guo XB, Zheng QJ, et al. [A randomized comparative study of naphtoquine, mefloquine and artsunate in the treatment of falciparum malaria]. Zhonghua Yi Xue Za Zhi 2003;83:1406-8
   PubMedGoogle Scholar
• Wang SQ, Meng F, Shen H, et al. [Therapeutic effect of dihydroartemisinin combined with naphthoquine phosphate in patients with falciparum malaria]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2002;20:180-2
   PubMedGoogle Scholar
• Faye B, Ndiaye JL, Ndiaye D, et al. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J 2007;6:80
   PubMedGoogle Scholar
• Amuasi JH, Diap G, Nguah SB, et al. Access to artemisinin-combination therapy (ACT) and other anti-malarials: national policy and markets in Sierra Leone. PLoS One 2012;7:e47733
   PubMedGoogle Scholar
• Diap G, Amuasi J, Boakye I, et al. Anti-malarial market and policy surveys in sub-Saharan Africa. Malar J 2010;9(Suppl 1):S1
   PubMedGoogle Scholar
• Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366:717-25
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010;376:1647-57
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Angus BJ. Malaria: severe, life-threatening. Clin Evid (Online) 2011;2011. pii: 0913.
   PubMedGoogle Scholar
• Hien TT, Davis TM, Chuong LV, et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother 2004;48:4234-9
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Reeder J, Lorry K, et al. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob Agents Chemother 2006;50:968-74
   PubMed Web of Science ®Google Scholar
• Li Q, Hickman M. Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology 2011;279:1-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria–worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep 2013;62:5-8
   PubMedGoogle Scholar
• Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011;17:771-7
   PubMed Web of Science ®Google Scholar
• Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J 2012;11:102
   PubMedGoogle Scholar
• Rolling T, Agbenyega T, Issifou S, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria-a double-center prospective study. J Infect Dis 2014;209:1921-8
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Coltart CE, Pule M, et al. Artemisinin therapy and severe delayed haemolysis. Lancet 2013;382:180
   PubMedGoogle Scholar
• Gomes MF, Faiz MA, Gyapong JO, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009;373:557-66
   PubMed Web of Science ®Google Scholar
• Grobusch MP. Early rectal artesunate administration: a life-saver in remote areas? Future Microbiol 2009;4:397-400
   PubMed Web of Science ®Google Scholar
• Okebe J, Eisenhut M. Pre-referral rectal artesunate for severe malaria. Cochrane Database Syst Rev 2014;5:CD009964
   Google Scholar
• Meremikwu MM, Odigwe CC, Akudo Nwagbara B, et al. Antipyretic measures for treating fever in malaria. Cochrane Database Syst Rev 2012;9:CD002151
   Google Scholar
• Maude RJ, Silamut K, Plewes K, et al. Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. J Infect Dis 2014;209:120-9
   PubMed Web of Science ®Google Scholar
• Shaz BH, Schwartz J, Winters JL, et al. American society for apheresis guidelines support use of red cell exchange transfusion for severe malaria with high parasitemia. Clin Infect Dis 2014;58:302-3
   PubMedGoogle Scholar
• Tan KR, Wiegand RE, Arguin PM. Exchange transfusion for severe malaria: evidence base and literature review. Clin Infect Dis 2013;57:923-8
   PubMed Web of Science ®Google Scholar
• Kreeftmeijer-Vegter AR, Melo Mde M, de Vries PJ, et al. Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria. Malar J 2013;12:115
   PubMedGoogle Scholar
• Santana-Cabrera L, Fernandez Arroyo M, Rodriguez Gonzalez F, et al. Erythrocytapheresis in the emergency management of severe falciparum malaria. J Emerg Trauma Shock 2010;3:206
   PubMedGoogle Scholar
• Dondorp AM, Nyanoti M, Kager PA, et al. The role of reduced red cell deformability in the pathogenesis of severe falciparum malaria and its restoration by blood transfusion. Trans R Soc Trop Med Hyg 2002;96:282-6
   PubMed Web of Science ®Google Scholar
• DTG. DGfTuIG: treatment of malaria (German guidelines). 2013. Available from: http://www.dtg.org/uploads/media/Malaria_2013_01.pdf
   Google Scholar
• Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46:165-71
   PubMed Web of Science ®Google Scholar
• Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013;26:165-84
   PubMed Web of Science ®Google Scholar
• Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010;10:405-16
   PubMed Web of Science ®Google Scholar
• Griffith KS, Lewis LS, Mali S, et al. Treatment of malaria in the United States: a systematic review. Jama 2007;297:2264-77
   PubMed Web of Science ®Google Scholar
• Pasaribu AP, Chokejindachai W, Sirivichayakul C, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis 2013;208:1906-13
   PubMed Web of Science ®Google Scholar
• Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007;44:1067-74
   PubMed Web of Science ®Google Scholar
• Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009;22:430-5
   PubMed Web of Science ®Google Scholar
• Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1955;46:301-6
   PubMed Web of Science ®Google Scholar
• Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75:402-15
   PubMed Web of Science ®Google Scholar
• White NJ, Qiao LG, Qi G, et al. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012;11:418
   PubMed Web of Science ®Google Scholar
• Eziefula AC, Bousema T, Yeung S, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014;14:130-9
   PubMed Web of Science ®Google Scholar
• Hwang J, Alemayehu BH, Reithinger R, et al. In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia. PLoS One 2013;8:e63433
   PubMedGoogle Scholar
• Yohannes AM, Teklehaimanot A, Bergqvist Y, et al. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg 2011;84:137-40
   PubMed Web of Science ®Google Scholar
• Krudsood S, Tangpukdee N, Muangnoicharoen S, et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 2007;45:111-14
   PubMedGoogle Scholar
• Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011;53:977-84
   PubMed Web of Science ®Google Scholar
• Lon C, Manning JE, Vanachayangkul P, et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One 2014;9:e93138
   PubMed Web of Science ®Google Scholar
• Senn N, Rarau P, Manong D, et al. Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea. Clin Infect Dis 2013;56:1413-20
   PubMed Web of Science ®Google Scholar
• Abdallah TM, Ali AA, Bakri M, et al. Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan. Malar J 2012;11:404
   PubMedGoogle Scholar
• Mombo-Ngoma G, Kleine C, Basra A, et al. Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. Malar J 2012;11:120
   PubMed Web of Science ®Google Scholar
• Liu H, Yang HL, Xu JW, et al. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J 2013;12:409
   PubMedGoogle Scholar
• Sutanto I, Tjahjono B, Basri H, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 2013;57:1128-35
   PubMed Web of Science ®Google Scholar
• Fatih FA, Staines HM, Siner A, et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malar J 2013;12:425
   PubMedGoogle Scholar
• Sevene E, Gonzalez R, Menendez C. Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother 2010;11:1277-93
   PubMed Web of Science ®Google Scholar
• Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 2013;309:594-604
   PubMed Web of Science ®Google Scholar
• Bardaji A, Bassat Q, Alonso PL, et al. Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence. Expert Opin Pharmacother 2012;13:1719-36
   PubMed Web of Science ®Google Scholar
• Hill J, Hoyt J, van Eijk AM, et al. Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med 2013;10:e1001488
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Blumentals WA, Suter P, et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012;54:e124-31
   PubMed Web of Science ®Google Scholar
• Jaroensuk J, Stoesser N, Leimanis ML, et al. Treatment of suspected hyper-reactive malarial splenomegaly (HMS) in pregnancy with mefloquine. Am J Trop Med Hyg 2014;90:609-11
   PubMed Web of Science ®Google Scholar
• Clark RL, Lerman SA, Cox EM, et al. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res B Dev Reprod Toxicol 2008;83:397-406
   PubMed Web of Science ®Google Scholar
• Longo M, Zanoncelli S, Torre PD, et al. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. Reprod Toxicol 2006;22:797-810
   PubMedGoogle Scholar
• Longo M, Zanoncelli S, Manera D, et al. Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol 2006;21:83-93
   PubMedGoogle Scholar
• Manyando C, Kayentao K, D’Alessandro U, et al. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malar J 2012;11:141
   PubMedGoogle Scholar
• Clark RL. Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients. Birth Defects Res A Clin Mol Teratol 2012;94:61-75
   PubMedGoogle Scholar
• McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 2001;33:2009-16
   PubMed Web of Science ®Google Scholar
• McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012;12:388-96
   PubMed Web of Science ®Google Scholar
• McGready R, Phyo AP, Rijken MJ, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol 2012;73:467-77
   PubMed Web of Science ®Google Scholar
• Adam I, Elhassan EM, Omer EM, et al. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann Trop Med Parasitol 2009;103:205-10
   PubMed Web of Science ®Google Scholar
• Deen JL, von Seidlein L, Pinder M, et al. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001;95:424-8
   PubMed Web of Science ®Google Scholar
• Manyando C, Mkandawire R, Puma L, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J 2010;9:249
   PubMed Web of Science ®Google Scholar
• Mosha D, Mazuguni F, Mrema S, et al. Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malar J 2014;13:197
   PubMed Web of Science ®Google Scholar
• Sangare LR, Weiss NS, Brentlinger PE, et al. Patterns of anti-malarial drug treatment among pregnant women in Uganda. Malar J 2011;10:152
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Muze K, Ord R, et al. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PLoS One 2009;4:e5138
   PubMed Web of Science ®Google Scholar
• McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med 2008;5:e253
   PubMed Web of Science ®Google Scholar
• Kalilani L, Mofolo I, Chaponda M, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One 2007;2:e1166
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Hellgren U, Greenwood B, et al. Mefloquine safety and tolerability in pregnancy: a systematic literature review. Malar J 2014;13:75
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006;62:1021-31
   PubMed Web of Science ®Google Scholar
• Kaye DK, Nshemerirwe R, Mutyaba TS, et al. A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J Infect Dev Ctries 2008;2:135-9
   PubMed Web of Science ®Google Scholar
• Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis 2010;10:762-9
   PubMed Web of Science ®Google Scholar
• Chaikitgosiyakul S, Rijken MJ, Muehlenbachs A, et al. A morphometric and histological study of placental malaria shows significant changes to villous architecture in both Plasmodium falciparum and Plasmodium vivax infection. Malar J 2014;13:4
   PubMedGoogle Scholar
• McGready R, Keo NK, Villegas L, et al. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R Soc Trop Med Hyg 2003;97:592-4
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Edstein MD, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003;59:545-52
   PubMed Web of Science ®Google Scholar
• Rulisa S, Kaligirwa N, Agaba S, et al. Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda. Malar J 2012;11:225
   PubMed Web of Science ®Google Scholar
• Tarning J, Kloprogge F, Piola P, et al. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J 2012;11:293
   PubMed Web of Science ®Google Scholar
• Rijken MJ, McGready R, Jullien V, et al. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob Agents Chemother 2011;55:4338-42
   PubMed Web of Science ®Google Scholar
• Tagbor H, Bruce J, Browne E, et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet 2006;368:1349-56
   PubMed Web of Science ®Google Scholar
• McGready R, Cho T, Samuel et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2001;95:651-6
   PubMed Web of Science ®Google Scholar
• McGready R, Ashley EA, Moo E, et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 2005;192:846-53
   PubMed Web of Science ®Google Scholar
• Adam I, Ali DA, Alwaseila A, et al. Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan. Saudi Med J 2004;25:1400-2
   PubMed Web of Science ®Google Scholar
• McGready R, Brockman A, Cho T, et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2000;94:689-93
   PubMed Web of Science ®Google Scholar
• Sowunmi A, Oduola AM, Ogundahunsi OA, et al. Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J Obstet Gynaecol 1998;18:322-7
   PubMedGoogle Scholar
• Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009;7:2-6
   PubMed Web of Science ®Google Scholar
• Rijken MJ, McGready R, Phyo AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2011;55:5500-6
   PubMed Web of Science ®Google Scholar
• Tarning J, Rijken MJ, McGready R, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 2012;56:1997-2007
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet 2014;383:723-35
   PubMed Web of Science ®Google Scholar
• Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J 2013;12:385
   PubMed Web of Science ®Google Scholar
• Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007;45:1453-61
   PubMedGoogle Scholar
• Creek D, Bigira V, Arinaitwe E, et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Am J Trop Med Hyg 2010;83:873-5
   PubMed Web of Science ®Google Scholar
• Mens PF, Sawa P, van Amsterdam SM, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 2008;7:237
   PubMedGoogle Scholar
• Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008;359:2545-57
   PubMed Web of Science ®Google Scholar
• Katrak S, Gasasira A, Arinaitwe E, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 2009;8:272
   PubMed Web of Science ®Google Scholar
• Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008;3:e2390
   PubMed Web of Science ®Google Scholar
• Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011;8:e1001119
   PubMed Web of Science ®Google Scholar
• Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014;1:CD010927
   Google Scholar
• Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007;2:e20
   PubMedGoogle Scholar
• Martensson A, Stromberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005;41:1079-86
   PubMed Web of Science ®Google Scholar
• Meremikwu M, Alaribe A, Ejemot R, et al. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J 2006;5:43
   PubMed Web of Science ®Google Scholar
• Owusu-Agyei S, Asante KP, Owusu R, et al. An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS One 2008;3:e2530
   PubMed Web of Science ®Google Scholar
• Michael OS, Gbotosho GO, Folarin OA, et al. Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J 2010;9:335
   PubMedGoogle Scholar
• Faucher JF, Aubouy A, Adeothy A, et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis 2009;200:57-65
   PubMed Web of Science ®Google Scholar
• Kobbe R, Klein P, Adjei S, et al. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malar J 2008;7:261
   PubMed Web of Science ®Google Scholar
• Maiteki-Sebuguzi C, Jagannathan P, Yau VM, et al. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J 2008;7:106
   PubMedGoogle Scholar
• Bukirwa H, Yeka A, Kamya MR, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006;1:e7
   PubMedGoogle Scholar
• Falade CO, Ogundele AO, Yusuf BO, et al. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 2008;13:635-43
   PubMed Web of Science ®Google Scholar
• Gbotosho GO, Sowunmi A, Okuboyejo TM, et al. Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. Am J Trop Med Hyg 2011;84:813-19
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005;365:1474-80
   PubMed Web of Science ®Google Scholar
• Premji Z, Umeh RE, Owusu-Agyei S, et al. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One 2009;4:e6682
   PubMedGoogle Scholar
• Toure OA, Kouame MG, Didier YJ, et al. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote d’Ivoire. Trop Med Int Health 2011;16:290-7
   PubMed Web of Science ®Google Scholar
• Faye B, Ndiaye JL, Tine R, et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am J Trop Med Hyg 2010;82:140-4
   PubMed Web of Science ®Google Scholar
• Sykes A, Hendriksen I, Mtove G, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 2009;49:1195-201
   PubMed Web of Science ®Google Scholar
• Prevention. CfDCa: Guidelines for Treatment of Malaria in the United States. Edited by; 2013
   Google Scholar
• Lalloo DG, Hill DR. Preventing malaria in travellers. BMJ 2008;336:1362-6
   PubMed Web of Science ®Google Scholar
• Lalloo DG, Shingadia D, Pasvol G, et al. UK malaria treatment guidelines. J Infect 2007;54:111-21
   PubMed Web of Science ®Google Scholar
• Bouchaud O, Muhlberger N, Parola P, et al. Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J 2012;11:212
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. Edited by U.S. Food and Drug Administration (FDA), Rockville, MD; 2013. Available from: http://www.fda.gov/drugs/drugsafety/ucm362227.htm [Last accessed 19 July 2014]
   Google Scholar
• Schlagenhauf P, Adamcova M, Regep L, et al. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010;9:357
   PubMed Web of Science ®Google Scholar
• Cramer JP, Lopez-Velez R, Burchard GD, et al. Treatment of imported severe malaria with artesunate instead of quinine–more evidence needed? Malar J 2011;10:256
   PubMedGoogle Scholar
• Noubiap JJ. Shifting from quinine to artesunate as first-line treatment of severe malaria in children and adults: saving more lives. J Infect Public Health 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Ward SA, Sevene EJ, Hastings IM, et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007;7:136-44
   PubMed Web of Science ®Google Scholar
• Kalilani-Phiri L, Thesing PC, Nyirenda OM, et al. Timing of malaria infection during pregnancy has characteristic maternal, infant and placental outcomes. PLoS One 2013;8:e74643
   PubMedGoogle Scholar
• Barber BE, William T, Grigg MJ, et al.A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013;56:383-97
   PubMed Web of Science ®Google Scholar
• Awab GR, Pukrittayakamee S, Imwong M, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J 2010;9:105
   PubMed Web of Science ®Google Scholar
• Krudsood S, Tangpukdee N, Wilairatana P, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2008;78:736-40
   PubMed Web of Science ®Google Scholar
• McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg 2002;96:180-4
   PubMed Web of Science ®Google Scholar
• Tarning J, Chotsiri P, Jullien V, et al. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother 2012;56:5764-73
   PubMed Web of Science ®Google Scholar
• Muehlenbachs A, Nabasumba C, McGready R, et al. Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial. Malar J 2012;11:150
   PubMedGoogle Scholar
• Adam I, Tarning J, Lindegardh N, et al. Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2012;87:35-40
   PubMed Web of Science ®Google Scholar
• Morris CA, Onyamboko MA, Capparelli E, et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J 2011;10:114
   PubMed Web of Science ®Google Scholar
• Nyunt MM, Adam I, Kayentao K, et al. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther 2010;87:226-34
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Salman S, Mueller I, et al. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob Agents Chemother 2010;54:1186-92
   PubMed Web of Science ®Google Scholar
• Tarning J, McGready R, Lindegardh N, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009;53:3837-46
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K, Manyando C, Ruengweerayut R, et al. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol 2005;61:573-82
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Ward SA, et al. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006;62(5):367-71
   PubMed Web of Science ®Google Scholar